Accelerating Medicines Partnership - Alzheimer's Disease

Watch this video to learn more about the AMP-AD Project.

The Accelerating Medicines Partnership Alzheimer’s Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. This multisector partnership is managed by the Foundation for the NIH. The combined public and private sector funding support for this 5-year endeavor is ~$185.2 million dollars. The AMP provides participating organizations the chance to collaborate on research on a scale that would not be possible for individual companies. Moreover, through close coordination the AMP provides not only access to data and analyses but also the ability to leverage substantial scientific and financial resources provided in partnership with the National Institutes of Health and academic researchers. AMP-AD is comprised of two projects: Project A is supplementing biomarker panels already included in three NIH-funded Phase II/III registration trials in presymptomatic AD through the addition of tau PET imaging and novel fluid biomarkers. Project B integrates analysis of large-scale molecular data from human brain samples with network modeling approaches and experimental validation, and enables rapid, broad sharing of data and analytical tools.

Read the NIA’s description of the program here. To learn about the AMP Type 2 Diabetes Project click here, the AMP RA/SLE Project click here or the AMP Parkinson's Disease Project click here.

Results & Accomplishments

AMP-AD Knowledge Portal

Click here to discover and download Alzheimer's Disease data, analyses and tools from the AMP-AD consortium program 

AMP-AD Agora Platform

Agora hosts evidence for whether or not genes are associated with Alzheimer's disease (AD). Agora also contains a list of close to 100 nascent drug targets for AD that were nominated by AD researchers. This initial list of nominated targets has been contributed by researchers from the AMP-AD consoritum. Click here to learn more.

Scientific Publications

  Data Descriptor Manuscripts (published in Nature Scientific Data):

The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Wang M et al. Scientific Data 5:180185. doi: 10.1038/sdata.2018.185. (2018 Sept 11)

A mutli-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. De Jager PL et al. Scientific Data 5:180142 doi: 10.1038/sdata.2018.142. (2018 Aug 7)

Global quantitive analysis of human brain proteome in Alzheimer's and Parkinson's Disease. Ping L et al. Scientific Data 5:180036 doi: 10.1038/sdata.2018.36 (2018 Mar 13).  

Generation and quality control of lipidomics data for the alzheimer's disease neuroimaging initiative cohort. Barupal DK et al. Scientific Data 5:180263. doi:10.1038/sdata.2018.263 (2018 Nov 20)

Targeted metabolomics and medication classification data from participants in the ADNI 1 cohort. St John-Williams L et al. Scientific Data 4:170140. doi: 10.1038/sdata.2017.140. (2017 Oct 17) 

Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Allen M et al. Scientific Data 3:160089. doi: 10.1038/sdata.2016.89. (2016 Oct 11) 

  Selected Research Manuscripts by Individual Teams (Preprints and Published work):

The Alzheimer's Disease Metabolome: Effects of Sex and APOE ε4 genotype. Matthias A. et al. bioRxiv 585455. doi: (2019)

Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Nho K et al. Alzheimer's Dement.15(2):232-244. doi: 10.1016/j.jalz.2018.08.012. (2019)

Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in cerebral Aβ amyloidosis mouse normalizes clinical phenotype and complement subnetwork molecular pathology without reducing Aβ burden. Haure-Mirande JV et al. Mol Psychiatry. doi: 10.1038/s41380-018-0255-6. (2019)

Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age. Wingo AP et al. Nat Commun. doi: 10.1038/s41467-019-09613-z. (2019)

Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer's disease susceptibility. Raj T et al. Nat Genet. doi: 10.1038/s41588-018-0238-1. (2018)

Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Johnson ECB et al. Mol Neurodegener. doi: 10.1186/s13024-018-0282-4. (2018)

A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease. Mostafavi S et al. Nat Neurosci. doi: 10.1038/s41593-018-0154-9. (2018)

A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. Seyfried NT et al. Cell Syst. 4(1):60-72. (2017)

An xQTL map integrates the genetic architecture of the human brain's transcriptome and epigenome. Ng B et al. Nat Neurosci. (10):1418-1426. (2017)

Metabolic network failures in Alzheimer's disease: A biochemical roadmap. Toledo JB et al. Alzheimer's Dement.(9):965-984. doi: 10.1016/j.jalz.2017.01.020. (2017)

Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer's disease. McKenzie AT et al. MOl Neurodegener 12(1):82. (2017)

Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Allen M et al. Alzheimer's Dement. pii:S1552-5260(17)33766-4. (2017)


National Institute on Aging Press Release (October 1, 2019): NIH-funded translational research centers to speed, diversify Alzheimer's drug discovery

Nature Reviews Drug Discovery (February 27, 2019): Massive NIH-industry project opens portals to target validation


Public-Sector Partners:
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
U.S. Food and Drug Administration (FDA)

Private-Sector Partners:
AbbVie Inc.
Alliance for Aging Research
Alzheimer's Association
Alzheimer’s Drug Discovery Foundation
Eli Lilly and Company
The Geoffrey Beene Foundation Alzheimer's Initiative
Vradenburg Foundation

FNIH Contact

Eline Appelmans, M.D., MPH, BMedSci, Scientific Project Manager, Neuroscience,